2009
ICAAC
Disk Diffusion testing of CXA-101 and CXA-101 in Combination with Tazobactam against Target Pathogens (F1-1998)
Activity Profile of CXA-101 and CXA-101/tazobactam against Target Gram-positive and Gram-negative Pathogens (F1-1986)
Resistance Trends among Gram-positive Cocci across the US and the Activity Profile of Tigecycline against Resistant Isolates (C2-1957)
Activity Profile of Tigecycline (TIG) against Resistant (R ) Gram-negative (GN) Enterobacteriaceae (EN) in the US (C2-1956)
Carbapenem and Other Antipseudomonal Agents: In Vitro Activity among Lower Respiratory Tract and ICU Isolates of P. aeruginosa: 2006-2008 TRUST Data (C2-629)
In vitro Activity of Radezolid against MRSA Causing Skin and Wound Infections from the United States, Europe, and Asia (E-810)
In vitro Activity of TR-700 (Torezolid) and Linezolid against Gram-positive Clinical Isolates from a Phase 2 Complicated Skin Clinical Trial (C1-1364a)
Activity of Ceftazidime/NXL104 and Select Comparators against Geographically Diverse Clinical Isolates of Pseudomonas aeruginosa (E-194)
ICC Satellite Symposium
Antimicrobial susceptibility trends among respiratory pathogens: What are global surveillance initiatives telling us?
ECCMID
Activity profile of empiric respiratory tract infection agents against Streptococcus pneumoniae in Europe based on patient population (P1634)
Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008 (P1620)
A current look at the in vitro activity of oritavancin and vancomycin against isolates of S. aureus from both Europe and the US (P1637)
Activity of tigecycline against Acinetobacter spp. from various specimen sources collected in Europe over the past five years (P1590)
Profile of tigecycline and comparator agents against Gram-positive organisms collected across the United States and Europe in 2007-2008 (P1613)
Profile of tigecycline and other agents against enteric bacilli collected across Europe (P1607)
IDSA
Regional Prevalence of Methicillin-Resistant S. aureus (MRSA) and Analysis of Ceftobiprole Activity against MRSA from 2006-2008─Results from TRUST and TSN Surveillance
Activity Profile of Tigecycline against Prevalent Multi-drug Resistant Populations of Acinetobacter spp. in the United States
ISAAR
Tigecycline Activity against Gram-Positive and Gram-Negative Target Pathogens from Asia in 2007, including Isolates with Multidrug Resistance (SR 35)
SHEA
Longitudinal Analysis of the Susceptibility of E. coli to Empiric Urinary Tract Infection (UTI) Agents; Impact of the Introduction of Generic Ciprofloxacin on Fluoroquinolone Resistance (476)
ASM
Activity Profile of Carbapenems Against Gram-Negative Pathogens; Impact of Using Pharmacodynamic (PD) Breakpoints vs. Current Interpretive Criteria (A020)
Current Resistance Across the US Among Enterobacteriaceae and P. aeruginosa; Regional Antibiogram of Doripenem and Comparators (A088)
Resistance Mechanisms in Ciprofloxacin-Resistant Escherichia coli Compared to Levofloxacin (A055)
2008
ICAAC/IDSA
Activity Profile of CXA-101against Gram-Positive and Gram-Negative Pathogens by Broth and AgarDilution
Mode of Action of CXA-101 Basedon Minimum Bactericidal Concentration (MBC) Analysis and Timekill Kinetic(TK) Analysis
Effect of Various TestingParameters on the Activity of CXA-101 by Broth Microdilution
Levofloxacin Susceptibility of S.pneumoniae (SP) and H. influenzae (HI) from Various Age GroupsAcross Asia: Results from GLOBALSurveillance Program
Activity of NZ2114 against Staphylococcaland Streptococcal Isolates, Including Resistant Phenotypes
Minimum BactericidalConcentration (MBC) Analysis and Timekill Kinetic (TK) Analysis of NZ2114against Staphylococci and Streptococci
Common Sources of S. aureus Infectionin the US and Prevalence of MRSA; Longitudinal Analysis of CeftobiproleActivity Against S. aureus from Prevalent Specimen Sources
Doripenem activity againstrecent Enterobacteriaceae from the US and resistant entericpopulations, including those with putative carbapenemases
In vitro Activity ofOritavancin against Gram-positive Organisms in Europe: A Comparative Study of Clinical Trialand Surveillance Results
Tigecycline Activity Profileagainst Acinetobacter baumannii: Comparative Study of a Recent CentralizedBroth Microdilution Surveillance Initiative and Results from LocalLaboratory Testing by E-test
Comparison of the TigecyclineEnterobacteriaceae Activity Profiles in the US Generated from CentralizedSurveillance by Broth Microdilution and from Localized Testing by VITEK2
Current In Vitro Activity ofTigecycline against Streptococcus pneumoniae and Haemophilus influenzaeIsolates from the UnitedStates
ECCMID
Anti-enterococcaland anti-sreptococcal activity profile of oritavancin in Europe
Invitro activity profile of oritavancin against resistant staphylococcalpopulations from a recent surveillance initiative in Europe
Tigecyclineactivity against Staphylococcus aureus exhibiting multidrug-resistantphenotypes in Europe
Analysisof tigecycline activity against Staphylococcus aureus based on patient locationand clinical specimen source in Europe
Susceptibilityof Staphylococcus aureus among skin and wound specimen sources in the United States:laboratory-based surveillance study 2005-2007
Alongitudinal perspective on Streptococcous pneumoniae, Haemophilus influenzae,and Moraxella catarrhalis resistance trends in Europe:from GLOBAL surveillance studies
Invitro activity of ceftobiprole against select Gram-positive and Gram-negative pathogensisolated from Europe in 2006-2007
Analysisof tigecycline activity against Enterobacteriaceae and Acinetobacter spp. basedon patient location and clinical specimen source in Europe
Tigecyclineactivity against geographically diverse Acinetobacter spp. displayingmulti-drug resistant phenotypes across Europe
Invitro activity of doripenem relative to meropenem and imipenem againstEnterobacteriaceae and P. aeruginosa isolates from Europe(2006-2007)
Tigecyclineactivity against geographically diverse Enterobacteriaceae displaying multidrug-resistant phenotypes across Europe
Currentsusceptibility patterns for H. influenzae and M. catarrhalis isolates from Europe: findings of the 2007 GLOBAL surveillance program
Epidemiologyof elevated fluoroquinolone MICs of S. pneumoniae, H. influenzae, and M.catarrhalis from the GLOBAL Study (1999-2005)
2007
ICAAC
Analysis of Doripenem Activity, Relative to Other Carbapenems, Against Target Gram-Negative Pathogens Isolated From Specific Infection Sites
A Longitudinal Perspective of Tigecycline Activity in the US against Staphylococcus aureus, Acinetobacter spp., and Enterobacteriaceae Exhibiting Multi-drug Resistant (MDR) Phenotypes
A Profile of Ceftobiprole (BPR) Activity Against Recent US Isolates of Enterobacteriaceae (EN) and Pseudomonas aeruginosa (PA) From Inpatients and ICU Patients
In Vitro activity of iclaprim against clinical isolates of Legionella pneumophila
Baseline Surveillance Profile of Cethromycin Activity against Streptococcus pneumoniae (SP); Results of the US Surveillance Initiative
Stratified Analysis of Doripenem Activity Against Enterobacteriaceae and Pseudomonas aeruginosa According to Patient Location: Inpatients and ICU Patients
7. Comparative Activities of Tigecycline among Recent Surveillance Isolates Tested by E-test and Broth Microdilution
5-Year Surveillance (2003-2007) of Anti-pneumococcal Activity of Oral Agents Recommended for the Empirical Treatment of Community Aquired Pneumonia (CAP) in Adults
Anti-Streptococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use against Gram-Positive Infections
In Vitro Activity Profile of Oritavancin against Resistant Staphylococcal Populations from a Recent Surveillance Initiative
In Vitro Activity Profile of Ceftobiprole (BPR), a Broad-Spectrum Anti-MRSA Cephalosporin, Against Recent S. aureus (SA) Isolated From Specific Clinical Specimens
In Vitro Activity of Cethromycin against a Recent and Diverse Collection of Haemophilus influenzae Isolates
Newly Defined in Vitro Quality Control Ranges for Oritavancin Broth Microdilution Testing and the Effect of Variations in Testing Conditions on MIC Results
Anti-Enterococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use against Gram-Positive Infections
In Vitro Activity Profile of Oritavancin against a Broad Spectrum of Aerobic and Anaerobic Bacterial Pathogens
Bactericidal activity and post antibiotic effect of iclaprim (ICL) against Staphylococcus aureus (SA)
Iclaprim (ICL): Defined quality control (QC) limits for MIC and disk diffusion (DD) susceptibility testing according to CLSI M23-A2 procedures
In Vitro Activity Profile of Oritavancin (ORI) against Organisms Demonstrating Key Resistance Profiles to Other Antimicrobial Agents
IDSA
Analysis of Levofloxacin and Comparator Antibiograms against Urinary Tract Infection (UTI) Isolates of E. coli and Other Enterobacteriaceae Across the United States
Surveillance Profiling of Doripenem Activity Against Pseudomonas aeruginosa Isolated From Inpatients and ICU Patients: Results of the TRUST Surveillance Initiatives
Ceftobiprole (BPR) Activity Against MRSA Stratified According to Patient Population and Specimen Source: Results of the Recent TRUST Surveillance Initiative
ECCMID
Europe Surveillance Initiative Profiling the Activity of Telavancin Against Streptococci by Specimen Source From 2004 to 2005
Baseline Surveillance Profile of Doripenem Against Key Gram-Negative Pathogens Encountered in Europe
Profile of Ceftobiprole Activity Against S. aureus, S. pneumoniae, Enterobacteriaceae, P. aeruginosa and Acinetobacter spp.: Results of the 2005-2006 Surveillance Program
Europe Surveillance Initiative Profiling the Anti-staphylococcal Activity of Telavancin by Specimen Source from 2004 to 2005
Europe Surveillance Initiative Profiling the Anti-enterococcal Activity of Telavancin by Specimen Source from 2004 to 2005
Analysis of Tigecycline Activity against Acinetobacter spp. and Enterobacteriaceae Based on Clinical Specimen Source
Current Susceptibility Patterns for Streptococcus pneumoniae and Haemophilus influenzae Isolates from Europe: Findings of the 2005-2006 GLOBAL Surveillance Program
Evalutation of Isavuconazole E-test Compared to Broth Microdilution Antifungal Susceptibility Testing against Quality Control Strains and Clinical Candida Isolates
Baseline Profile of RO4908463 (CS-023) against Recent Isolates of Target Gram-Negative Pathogens Exhibiting ß-Lactam Resistant Phenotypes from Europe (EU), 2003-2006
Comparison of Baseline Profiles of RO4908463 (CS-023) against Recent Isolates of Target Gram-Possitive Pathogens Exhibiting Key Resistance Phenotypes Obtained from Europe and the USA 2003-2006
2006
ICAAC
Increasing Prevalence of High Level Macrolide Resistance among Streptococcus pneumoniae in the United States
Comparative In Vitro Potency of Oritavancin, Teicoplanin, and Vancomycin against Glycopeptide-Susceptible and -Resistant Gram-Positive Organisms
Baseline Profile of Telavancin Activity against Streptococci: Results of the 2004-2005 US Surveillance Initiative
Interaction of Telavancin and Other Antrimicrobial Agents Tested against Key Gram-positive Species
In Vitro of Telavancin against Enterococci: Results of the 2004-2005 US Surveillance Initiative
Baseline Antistaphylococcal Profile of Telavancin: Results of the 2004-2005 US Surveillance Initiative
In Vitro Activity of API-1252, a Novel Antimicrobial Agent, against Select Methicillin-Resistant Staphylococcus aureus (MRSA) Strains Exhibiting Key Resistance Phenotypes
Activity of ME1036, a Novel Anti-MRSA Carbapenem, against Gram-Positive and Gram-Negative Pathogens
Baseline Profile of RO4908463 (CS-023) Against Recent Isolates of Target Gram-Positive Pathogens Exhibiting Key Resistance Phenotypes
Profile of Ceftobiprole (BPR) Activity Against Staphylococci and S. pneumoniae (SP): Results fo the 2005-2006 Surveillance Program
Baseline Surveillance Profiles of Ceftobiprole (BPR) Activity Against Enterobacteriaceae and P. aeruginosa (PA)
Discordant Levofloxacin (LV) and Ciprofloxacin (CP) Susceptibility Profiles among Common Gram-Negative Bacilli; Indication of Potential Differences in Mode of Action?
Telavancin Demonstrates a Low Potential for In Vitro Selection of Resistance among Key Target Gram-positive Species
Bactericidal Activity of RO4908463 (CS-023) Against Beta-Lactam-Susceptible and -Resistant Target Species
Baseline Profile of RO4908463 (CS-023) Against Recent Isolates of Target Gram-Negative Pathogens Exhibiting Beta-Lactam Resistance Phenotypes
RO4908463 (CS-023) Demonstrates a Low Potential for in vitro Selection of Resistance in S. aureus, S. pneumoniae, E. coli, E. cloacae, K. pneumoniae and P. aeruginosa
Surveillance of Tigecycline (TIG) Activty; Discordance between Natioinal Profiles Associated with Testing Protocol and Methods
Longitudinal Analysis of Tigecycline (TIG) Activity against Geographically Diverse Staphylococcus aureus (SA), Acinetobacter spp (AB), and Enterobacteriaceae (EN) Exhibiting Multi-drug Resistant (MDR) Penotypes
IDSA
Profiles of Tigecycline Activity Based on Patient Location and Clinical Specimen Source of Target Organisms
Baseline Surveillance of Telavancin In Vitro Activity against Staphylococci in Europe and Israel
Baseline Surveillance of Telavancin Activity against Enterococci in Europe and Israel
Antistreptococcal Profile of Telavancin Based of the 2004-2005 Surveillance Initiative in Europe and Israel
Fluoroquinolone Susceptibility Profiles of Recent Urinary Tract Isolates Obtained from Pediatric Patients
Increasing Prevalence of Multidrug Resistance Phenotypes among Staphylococcus aureus Encountered in the Outpatient Settings; Comparative Findings of the LEADER 2004 and 2005 Surveillance Programs
Longitudinal Analysis of Linezolid (LIN) Activity against Gram-positive Pathogens: Comparison of Results for the LEADER 2004 and 2005 US Surveillance Programs
Comparative Susceptibility Patterns of Levofloxacin and Other Agents against Pediatric Respiratory Tract Isolates of Streptococcus pneumoniae (SP)
ECCMID
A Current Perspective on Streptococcus pneumoniae and Haemophilus influenzae Resistance Trends in Europe: GLOBAL Surveillance Study 2005
Comparative Analysis of Levofloxacin and Ciprofloxacin Activity against Gram-Negative Pathogens Collected in Five European Countries Grouped by Site of Infection from GLOBAL Surveillance - 2005
Benchmarking Tigecycline Activity against Gram-positive and Gram-negative Pathogens with Multi-drug Resistance Phenotypes derived from Patient Specimens from the USA and Europe
2005
ICAAC
Screening of Levofloxacin-Susceptible Streptococcus pneumoniae Isolates from Clinical Trial Patients with Pneumonia for Mutations in parC or parE: Clinical and Microbiological Outcomes
Baseline Tigecycline (TIG) Activity Against Current and Geographically Diverse Staphylococcus aureus (SA) Strains Exhibiting Key Resistance Phenotypes
Comparison of Antimicrobial Resistance Profiles between Inpatient and Outpatient Escherichia coli Populations
Telavancin Activity Against Current and Diverse Staphylococcus aureus Populations
Telavancin Activity Against Current and Diverse Populations of Enterococci and Streptococcus pneumoniae
In vitro Activity of Linezolid Against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program
Comparative Analysis of Antimicrobial Phenotypes between Streptococcus pneumoniae Populations Isolated from the Community and Hospital Settings
In Vitro Potency and Spectrum of Novel Rifamycins ABI-0043, ABI-0094, and ABI-0299
In Vitro Activity of Retapamulin and Comparators against 1690 Recent Gram-Positive Clinical Isolates
Dalbavancin Demonstrates a Low In Vitro Potential for Selection of Resistance in Staphylococci
IDSA
Antimicrobial Resistance Trends Among Sinus Isolates of Streptococcus pneumoniae from the United States: 2000-2005
Role of Efflux and QRDR Mutations among Streptococcus pneumoniae Isolates with Reduced Susceptibilities to Ciprofloxacin
Baseline Tigecycline (TIG) Activity Against a Diverse and Current Collection of Enterobacteriaceae (EB) and Acinetobacter (AC) Exhibiting Multi-drug Resistnace
Current Antimicrobial Resistance Profiles Among Methicillin-Resistant Staphylococcus aureus Encountered in the Outpatient Setting: Analysis of LEADER 2004 Surveillance Program Results
Ceftobiprole (BAL9141), an Investigational Cephalosporin With Activity Against MRSA, Demonstrates In Vitro Activity Against Clinical Isolates of Pseudomonas aeruginosa
ECCMID
A Baseline Assesment of the Activity of Telavancin against a Collection of Gram-Positive Isolates, including Resistant Phenotypes
Activity and Pharmacodynamics of RO4908463 (CS-023), a Unique Guanidine-Pyrrolidine Carbapenem with Activity against MRSA
Investigation of Divergent Piperacillin and Piperacillin/tazobactam Activities to Support Appropriate Formulary Decisions
The Prevalence of Multidrug Resistance Among Streptococcus pneumoniae (SP) in the USA
Activity of Ceftobiprole against Recent Clinical Isolates of Enterobacteriaceae from Respiratory Infections from Hospitalized Patients in Europe and USA
